FDA Seeks Input on Regulating AI-Enabled Medical Devices
The US Food and Drug Administration has released a discussion paper seeking public comment on a new regulatory framework for medical devices enabled by generative AI.
On August 18, 2026, the FDA's Digital Health Center of Excellence issued a discussion paper initiating a public dialogue on regulating medical devices that incorporate generative AI. The paper does not propose new rules but rather seeks stakeholder feedback on a range of issues, from ensuring algorithm safety and effectiveness to addressing potential bias and managing the entire product lifecycle of these rapidly evolving tools. For medical device manufacturers, software developers, and healthcare providers, this is a critical, early opportunity to shape future US regulatory policy in a high-growth sector. BigLaw clients in the life sciences and technology spaces are directly impacted, as their input can influence the direction of future draft guidance or formal rulemaking. The immediate action is for counsel to analyze the paper and advise clients on submitting comments to the FDA docket, which can help create a more predictable and innovation-friendly regulatory landscape.